Boehringer Ingelheim, Eli Lilly File NDA for Diabetes Combination ProductBy
Boehringer Ingelheim Pharmaceuticals, Inc. and
If granted approval by the
Boehringer Ingelheim’s linagliptin, marketed as TradjentaÂ®, was approved by FDA in 2011, and is a once-daily, 5-mg tablet used along with diet and exercise to improve glycemic control in adults with Type II diabetes. Empagliflozin is in Phase III development for treatment of Type II diabetes. .
Source: Eli Lilly